ArticleScientific reports2026
Bevacizumab-IRDye800 as an imaging probe for the detection of prostate cancer in mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Vascular endothelial growth factor (VEGF) signalling plays a critical role in carcinogenesis and tumour development in several types of cancer. Therefore, we sought to evaluate a fluorescently labelled monoclonal antibody against VEGF-A (Bevacizumab) as a probe for the detection of prostate cancer by in vivo fluorescence imaging. An orthotopic model of prostate cancer was generated by injecting bioluminescent human PC3 cells into the prostate lobe, followed by bioluminescence in vivo. Bevacizumab was labelled using a near-infrared fluorophore to generate a specific imaging probe (Bevacizumab-IRDye800). The probe was injected intravenously into prostate cancer-bearing mice, and fluorescence was monitored in vivo by fluorescence molecular tomography (FMT). 72 h post-injection, Bevacizumab-IRDye800 was detected in vivo by FMT in the prostate region. On excised prostates, the fluorescence signal overlaid with the bioluminescent signal from cancer cells. Our data demonstrate that Bevacizumab-IRDye800 is a high-affinity contrast agent for in vivo detection of prostate cancer tumours, paving the way to further development of near-infrared-labelled Bevacizumab-IRDye800 for the detection of other solid cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.